title: Impact of bone marker feedback on adherence to once monthly ibandronate for osteoporosis among Asian postmenopausal women.
abstract: OBJECTIVE
  This study assesses the impact of serum carboxy-terminal collagen crosslinks (CTX) bone marker feedback (BMF) on adherence to ibandronate treatment in Asian postmenopausal women with osteoporosis.
  
  
  METHODS
  This was a 12-month (6-monthly phased), randomized, prospective, open-label, multi-center study conducted in 596 (of 628 enrolled) postmenopausal women with osteoporosis (< or = 85 years old) who were naïve, lapsed, or current bisphosphonate users. Patients were randomized into two arms: serum CTX BMF at 3 months versus no-BMF. Once-monthly 150 mg ibandronate tablet was administered for 12 months and adherence to therapy was assessed at 6 and 12 months. In addition, patient satisfaction and safety of ibandronate treatment were also assessed.
  
  
  RESULTS
  Serum CTX BMF at 3 months showed no impact on adherence. The proportions of adherent patients were comparable in the BMF versus no-BMF arms (92.6%vs. 96.0%, P = 0.16); overall, serum CTX levels were similar for adherent and non-adherent patients. However, BMF patients felt more informed about their osteoporosis (P < 0.001) and more satisfied (P < 0.01) than no-BMF patients.
  
  
  CONCLUSIONS
  The Asian postmenopausal osteoporosis patients in this study had a high adherence rate to once-monthly ibandronate therapy. Use of serum CTX BMF had no further impact on increasing adherence, but increased treatment satisfaction.
authors.forename: Annie Wai-Chee
authors.initials: AW
authors.lastname: Kung
authors.forename: Ichramsjah A
authors.initials: IA
authors.lastname: Rachman
authors.forename: John M F
authors.initials: JM
authors.lastname: Adam
authors.forename: Djoko
authors.initials: D
authors.lastname: Roeshadi
authors.forename: Tito
authors.initials: T
authors.lastname: Torralba
authors.forename: Sandra
authors.initials: S
authors.lastname: Navarra
authors.forename: Zayda
authors.initials: Z
authors.lastname: Gamilla
authors.forename: Arthur
authors.initials: A
authors.lastname: Cañete
authors.forename: Miles
authors.initials: M
authors.lastname: de la Rosa
authors.forename: KehSung
authors.initials: K
authors.lastname: Tsai
authors.forename: Hsiao-Yi
authors.initials: HY
authors.lastname: Lin
authors.forename: Yung Kuei
authors.initials: YK
authors.lastname: Soong
authors.forename: Joung-Liang
authors.initials: JL
authors.lastname: Lan
authors.forename: Horng-Chaung
authors.initials: HC
authors.lastname: Hsu
authors.forename: Shih-Te
authors.initials: ST
authors.lastname: Tu
authors.forename: Ruey-Mo
authors.initials: RM
authors.lastname: Lin
authors.forename: Pongsak
authors.initials: P
authors.lastname: Yuktanandana
authors.forename: Thawee
authors.initials: T
authors.lastname: Songpatanasilp
authors.forename: Srihatach
authors.initials: S
authors.lastname: Ngarmukos
authors.forename: Sugree
authors.initials: S
authors.lastname: Soontrapa
authors.forename: Suppasin
authors.initials: S
authors.lastname: Soontrapa
authors.forename: Sattaya
authors.initials: S
authors.lastname: Rojanasthien
authors.forename: Sirichai
authors.initials: S
authors.lastname: Luevitoonvechkij
authors.forename: Taninnit
authors.initials: T
authors.lastname: Leerapan
authors.forename: Adelin
authors.initials: A
authors.lastname: Albert
authors.forename: Sophie
authors.initials: S
authors.lastname: Vanbelle
mesh_terms: D000284:Administration, Oral; D000368:Aged; D000369:Aged, 80 and over; D044466:Asian People; D015415:Biomarkers / Q000097:blood*; D050071:Bone Density Conservation Agents / Q000008:administration & dosage* / Q000009:adverse effects; D001842:Bone and Bones / Q000187:drug effects / Q000378:metabolism; D004164:Diphosphonates / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D006801:Humans; D000077557:Ibandronic Acid; D008875:Middle Aged; D015663:Osteoporosis, Postmenopausal / Q000378:metabolism* / Q000517:prevention & control*; D010349:Patient Compliance; D017060:Patient Satisfaction
chemical_list: D015415:Biomarkers; D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D000077557:Ibandronic Acid